Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D01IED
|
|||
| Former ID |
DIB008440
|
|||
| Drug Name |
BVD-523
|
|||
| Indication | Melanoma [ICD-11: 2C30; ICD-9: 172] | Phase 2 | [1] | |
| Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C76-C80; ICD-9: 140-229] | Phase 1/2 | [2] | ||
| Pancreatic cancer [ICD-11: 2C10; ICD-9: 185] | Phase 1 | [3] | ||
| Company |
Biomed valley discoveries
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C21H22Cl2N4O2
|
|||
| Canonical SMILES |
CC(C)NC1=NC=C(C(=C1)C2=CNC(=C2)C(=O)NC(CO)C3=CC(=CC=C3)Cl)Cl
|
|||
| InChI |
1S/C21H22Cl2N4O2/c1-12(2)26-20-8-16(17(23)10-25-20)14-7-18(24-9-14)21(29)27-19(11-28)13-4-3-5-15(22)6-13/h3-10,12,19,24,28H,11H2,1-2H3,(H,25,26)(H,27,29)/t19-/m1/s1
|
|||
| InChIKey |
KSERXGMCDHOLSS-LJQANCHMSA-N
|
|||
| CAS Number |
CAS 869886-67-9
|
|||
| PubChem Compound ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03417739) A Phase II Study of BVD-523 in Metastatic Uveal Melanoma. U.S. National Institutes of Health. | |||
| REF 2 | ClinicalTrials.gov (NCT01781429) Phase I Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of BVD-523 in Patients With Advanced Malignancies. U.S. National Institutes of Health. | |||
| REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 4 | DOI: 10.1158/1538-7445.AM2015-4693 | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.